PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: IMARC Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

U.S Biosimilar Market to Reach Revenues Worth US$ 11.4 Billion by 2020 Finds IMARC Group - A new report from IMARC Group expects the US biosimilar market to reach revenues worth US$ 11.4 Billion by 2020. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint
U.S Biosimilar Market to Reach Revenues Worth US$ 11.4 Billion by 2020 Finds IMARC Group

 

NewswireToday - /newswire/ - Delhi, India, 2011/07/26 - A new report from IMARC Group expects the US biosimilar market to reach revenues worth US$ 11.4 Billion by 2020. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be marathon and not a sprint. IMARC Group, one of the world’s leading research and advisory firms, in its new report entitled “US Biosimilar & Follow-On Biologics Market Report (2011-2020): Problems, Prospects & Projections” finds that with eighteen biopharmaceutical molecules expected to face biosimilar competition during 2011 and 2020, the market for biosimilars in the US is expected to reach values worth US$ 11.4 Billion by 2020.

Findings from the report suggest that the historical performance of Omnitrope cannot be taken as a benchmark to gauge the potential of pipeline biosimilars as market acceptance for each biosimilar class is expected to significantly vary from one another. The report expects competition between branded biological drugs and their biosimilar counterparts to represent more that of a brand-brand competition than a brand-generic competition. The high costs involved in the development and launch of biosimilars is expected to limit the number of players in this market and create a significantly lower price and volume erosion compared to small molecule generics.

Key Aspects Analyzed:

Understanding the Current Legislations on Biosimilars:
• An Insight into the Biologics Price Competition and Innovation Act
• An insight on the key biosimilar issues that still remain unaddressed
• Interchangeability and Substitutability
• Data Exclusivity
• Provisions for patent litigation

Evaluating the Current Market Landscape for Biosimilars:
• Identification of current marketed biosimilars and their historical performance
• Identifying the reasons for the slow uptake of current marketed biosimilars
• Analyzing historical data to formulate conclusions on the future growth and trends of biosimilars

Evaluating the Extent of Biosimilar Price, Sales and Volume Erosion:
• Analyzing historical time series data on price, volume and sales erosion in the US & Europe
• Analyzing previous models and assumptions on biosimilar price and volume erosion
• Evaluating and comparing biosimilar price and volume erosion with that of small molecule generics
• Evaluating and comparing biosimilar price, volume and sales erosion across various biological classes

Evaluating the Sales and Volume Erosion of Biosimilars across Various Molecules:
Molecules Covered: Somatropin, Epoitin Alfa, Darbepoetin Alfa, Filgrastim, Pegfilgrastim, Insulin Lispro, Insulin Glargin, Insulin Detemir, Interferon Beta-1A, Interferon Beta-1B, Bevacizumab, Trastuzumab, Rituximab, Cetuximab, Ethanercept, Infliximab and Adalimumab
Focus of the Analysis for Each Molecule:
• Historical Background and Overview
• Historical Brand Sales
• Brand and Biosimilar Sales Forecast

Evaluating the Sales of Biosimilars across Various Indications:
Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency
Focus of the Analysis for Each Indication:
• Historical Brand Sales
• Brand & Biosimilar Sales Forecast
• Biosimilar Sales Forecast by Molecule

Evaluating the Biosimilar Competitive Landscape:
• Identifying branded biological manufacturers that expect the highest amount of biosimilar erosion
• Identifying biosimilar manufacturers and their current partnerships and pipelines

Table of Contents:

1Market Definitions & Research Methodology
2Executive Summary
3Biosimilar Legislation in the US
3.1The Biologics Price Competition and Innovation Act: An Insight
3.2Biosimlar Issues that Still Remain Unaddressed
3.3Major Issues Impacting the Business Strategies of Biological Companies
3.3.1Interchangeability & Substitutability
3.3.2Data Exclusivity
3.3.3Patent Litigation
4The US Biosimilar Market Landscape
5US Biosimilar Market: Current Experience
5.1The Performance of Growth Hormone Biosimilars Has Been Dismal So Far
5.2Prescribing Patterns for Omnitrope
5.3Pediatrics Represent the Prime Customer Base of Growth Hormones
5.4Omnitrope was Launched with an Inconvenient Delivery Device
5.5Uptake is Likely to Increase with an Accumulation of a Positive Post-Market Safety Data
6US Biosimlar Market: How Much Price, Volume & Sales Erosion will Result
6.1Omnitrope Cannot be Taken as a Benchmark to Gauge the Performance of Other Biosimilars
6.2The European Uptake of ESA & GCSF Give Us a Very Positive Outlook for the US
6.3Current & Future Biosimilar Volume Erosion Across Various Biological Classes
6.4Current & Future Biosimilar Price Erosion Across Various Biological Classes
6.5Current & Future Biosimilar Sales Erosion Across Various Biological Classes
7US Biosimilar Market: Current Trends & Forecast by Drug
7.1Growth Hormones
7.2Erythropoiesis-Stimulating Agents
7.3Granulocyte Colony Stimulating Factor
7.4Insulin
7.5Interferons
7.6Oncology Monoclonal Antibody
7.7TNF Alpha
8US Biosimilar Market: Current Trends & Forecast by Indication
8.1Immunology & Inflammation
8.2Diabetes
9Competitive Landscape
9.1Branded Manufacturers: Companies Facing the Highest Amount of Biosimilar Erosion
9.2Biosimilar Manufacturers: Companies Gaining the Most From Biosimilar Launches
9.3Key Company Profiles

To buy the complete report or to get a free sample:

Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America)
For more information please visit imarcgroup.com or email sales[.]imarcgroup.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


U.S Biosimilar Market to Reach Revenues Worth US$ 11.4 Billion by 2020 Finds IMARC Group

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Krishna Sharma - IMARCgroup.com 
+91 12 04155099 press[.]imarcgroup.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IMARC Group / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Deb Sheppard - Medium Psychic Author Speaker

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)